A detailed history of Geode Capital Management, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 782,181 shares of NUVL stock, worth $66.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
782,181
Previous 681,596 14.76%
Holding current value
$66.5 Million
Previous $51.2 Million 15.93%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$62.76 - $81.61 $6.31 Million - $8.21 Million
100,585 Added 14.76%
782,181 $59.3 Million
Q1 2024

May 13, 2024

BUY
$72.35 - $88.99 $1.94 Million - $2.39 Million
26,849 Added 4.1%
681,596 $51.2 Million
Q4 2023

Feb 13, 2024

BUY
$42.42 - $80.28 $4.64 Million - $8.78 Million
109,398 Added 20.06%
654,747 $48.2 Million
Q3 2023

Nov 13, 2023

BUY
$39.12 - $49.85 $659,484 - $840,371
16,858 Added 3.19%
545,349 $25.1 Million
Q2 2023

Aug 11, 2023

BUY
$23.58 - $44.68 $1.13 Million - $2.15 Million
48,108 Added 10.01%
528,491 $22.3 Million
Q1 2023

May 15, 2023

BUY
$25.42 - $33.52 $610,893 - $805,552
24,032 Added 5.27%
480,383 $12.5 Million
Q4 2022

Feb 13, 2023

BUY
$18.46 - $36.37 $2.25 Million - $4.44 Million
122,062 Added 36.51%
456,351 $13.6 Million
Q3 2022

Nov 14, 2022

BUY
$13.55 - $19.92 $1.1 Million - $1.62 Million
81,111 Added 32.04%
334,289 $6.5 Million
Q2 2022

Aug 12, 2022

SELL
$7.4 - $15.07 $94,202 - $191,841
-12,730 Reduced 4.79%
253,178 $3.43 Million
Q1 2022

May 13, 2022

BUY
$11.65 - $19.57 $1.08 Million - $1.81 Million
92,504 Added 53.35%
265,908 $3.69 Million
Q4 2021

Feb 11, 2022

BUY
$18.01 - $30.1 $172,337 - $288,026
9,569 Added 5.84%
173,404 $3.3 Million
Q3 2021

Nov 12, 2021

BUY
$18.25 - $38.35 $2.99 Million - $6.28 Million
163,835 New
163,835 $3.69 Million

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $3.65B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.